Scientific Glossary

Administration route where the compound is injected into the fatty tissue just beneath the skin.

The subcutaneous layer sits between the skin and muscle. SubQ injections are typically made at a 45° angle using short needles (4-6mm). Commonly used in research for peptides due to consistent absorption rates. The fatty layer has less vascularity than muscle, resulting in slower, more sustained absorption compared to intramuscular injections.

Administration route where compounds are injected directly into muscle tissue.

IM injections deliver compounds directly into muscle tissue, which has rich blood supply. This results in faster absorption compared to subcutaneous administration. Common sites in research include the deltoid, vastus lateralis (outer thigh), and gluteus medius. Generally used when faster absorption kinetics are desired.

The time required for the concentration of a compound in the body to reduce by half.

Half-life (t½) describes how quickly a compound is eliminated from the body. After one half-life, 50% remains; after two, 25%; after five half-lives, roughly 3% remains (considered effectively cleared). Short half-life (minutes-hours) may require more frequent administration to maintain steady-state concentrations in research studies.

The fraction of an administered compound that reaches systemic circulation in active form.

Bioavailability (F%) is expressed as a percentage. IV administration = 100% bioavailability (reference). Subcutaneous and intramuscular routes typically achieve 70-100% for peptides. Oral bioavailability for most peptides is very low (often <1%) due to digestive enzyme degradation, which is why most research peptides are studied via injection. Nasal routes vary (Semax, Selank show meaningful CNS absorption intranasally).

A measure of total compound exposure over time — the integral of concentration vs. time curve.

AUC represents total drug exposure. A higher AUC indicates more compound reached systemic circulation over the measurement period. Used to compare bioavailability between routes and formulations. AUC₀₋∞ represents total exposure; AUC₀₋t is measured to a specific time point. Critical parameter in pharmacokinetic studies for determining dosing interval and accumulation potential.

Maximum (peak) plasma concentration achieved after administration.

Cmax is the highest blood concentration measured after a single dose. Occurs at Tmax (time to maximum concentration). Higher Cmax may correlate with stronger acute effects but also potentially more side effects. In peptide research, rapid Cmax followed by quick elimination is common due to short half-lives. Important for understanding the "peak and trough" cycle of compound exposure.

Time to reach maximum plasma concentration after administration.

Tmax tells researchers when a compound reaches its peak blood level. For subcutaneous peptides, Tmax typically ranges from 15 minutes to 2 hours depending on molecular size and local tissue factors. Intravenous administration has Tmax at infusion end. Understanding Tmax helps research teams time subsequent measurements and interpret pharmacodynamic effects relative to peak exposure.

The condition where drug input equals drug output, maintaining consistent plasma levels.

Steady state is reached after approximately 4-5 half-lives of regular dosing. At steady state, plasma concentrations oscillate predictably between a minimum (trough) and maximum (peak) without continuing to accumulate. For a compound with a 7-day half-life (like semaglutide), steady state requires roughly 5-6 weeks of weekly dosing. Most clinical trial efficacy data is measured at or near steady state.

The study of how the body processes a compound — absorption, distribution, metabolism, and excretion (ADME).

Pharmacokinetics describes what the body does to a compound. The ADME framework: Absorption (how the compound enters circulation), Distribution (where it goes in the body), Metabolism (how it's broken down), Excretion (how it's eliminated). For peptides, proteolytic degradation is the primary metabolic route. Understanding PK helps predict dosing frequency, accumulation risk, and exposure-response relationships.

The study of how a compound affects the body — its mechanisms, effects, and dose-response relationships.

Pharmacodynamics is the flip side of pharmacokinetics: what the compound does to the body. Includes receptor binding (affinity, selectivity), downstream signaling, therapeutic effects, and side effects. The PK/PD relationship links compound exposure (concentration) to observed response. Understanding PD helps explain why two compounds with similar structures may have very different biological effects.

The process of dissolving a lyophilized (freeze-dried) peptide powder into sterile liquid solution.

Most research peptides are manufactured and shipped as lyophilized (freeze-dried) powder to maximize stability and shelf life. Reconstitution involves adding an appropriate sterile diluent (typically bacteriostatic water) to create an injectable solution. The volume of diluent added determines the final concentration (e.g., adding 2mL to 5mg powder = 2.5mg/mL). Proper reconstitution technique is critical for accurate concentration and sterility.

Sterile water for injection containing 0.9% benzyl alcohol as a bacteriostatic preservative for multi-use vials.

Standard diluent for research peptide reconstitution. The 0.9% benzyl alcohol prevents bacterial growth after the vial is punctured, allowing multiple draws from the same vial (typically within 28 days). Important to note: bacteriostatic water is contraindicated in neonates due to benzyl alcohol toxicity risk. Sterile water for injection (no preservative) is a single-use alternative but must be used immediately after opening.

Freeze-drying process that removes moisture from compounds under vacuum, creating stable powder form.

Lyophilization (freeze-drying) involves freezing a compound solution and then reducing surrounding pressure to allow the frozen water to sublimate directly from solid to gas. This preserves compound integrity while creating a dry, stable powder. Lyophilized peptides are significantly more stable than aqueous solutions, allowing room temperature shipping and extended shelf life. Upon reconstitution, the compound returns to its biologically active form.

Incretin hormone secreted by intestinal L-cells in response to food intake. Regulates glucose homeostasis and satiety.

GLP-1 is released from the gut after meals and exerts multiple metabolic effects: stimulates glucose-dependent insulin secretion from pancreatic beta-cells, suppresses glucagon from alpha-cells, slows gastric emptying (creating satiety), and acts centrally to reduce appetite. GLP-1 has a very short endogenous half-life (~2 minutes) due to DPP-4 degradation. Pharmaceutical GLP-1 receptor agonists are engineered for much longer half-lives (days to weeks).

Incretin hormone secreted by intestinal K-cells. Potentiates insulin release and plays roles in fat storage and energy metabolism.

GIP is the other major incretin hormone. Like GLP-1, it stimulates insulin secretion in response to blood glucose elevation. However, GIP receptors are also expressed in adipose tissue and bone. The GIP receptor's role in fat metabolism is complex — it may promote fat storage in some contexts. Dual GIP/GLP-1 receptor agonists (like tirzepatide) leverage both pathways, potentially explaining their superior weight reduction vs. GLP-1 monotherapy.

Hypothalamic peptide that stimulates pituitary release of growth hormone in a pulsatile pattern.

GHRH is produced in the hypothalamus and travels to the anterior pituitary where it binds GHRH receptors on somatotroph cells, stimulating GH synthesis and secretion. Endogenous GHRH is released in pulses, particularly during deep sleep. Pharmaceutical GHRH analogues (sermorelin, CJC-1295, tesamorelin) extend this activity by increasing half-life. Importantly, GHRH-based compounds preserve the natural feedback loop — GH levels suppress further GHRH release, maintaining physiological regulation.

Synthetic peptides that stimulate GH secretion via ghrelin receptor pathway, independent of GHRH.

GHRPs are synthetic peptides that act on the ghrelin receptor (GHSR-1a) to stimulate GH release. Unlike GHRH, GHRPs do not require GHRH activity — they activate a complementary and synergistic pathway. When GHRH and GHRP are combined, GH pulses are dramatically amplified (2-10x in some studies) compared to either alone. This synergy is the scientific basis for GHRH+GHRP combination research protocols. Examples: ipamorelin, GHRP-6, hexarelin.

Primary mediator of GH effects. Produced mainly in the liver in response to GH stimulation.

IGF-1 is a 70-amino-acid protein that mediates most of growth hormone's anabolic and mitogenic effects. GH stimulates hepatic IGF-1 production; IGF-1 then travels systemically to promote protein synthesis, cell proliferation, and glucose uptake. IGF-1 provides negative feedback on GH secretion. Serum IGF-1 is used as a clinical marker for GH status because it reflects integrated GH secretion over time (more stable than measuring pulsatile GH directly).

Reduction in receptor number or sensitivity following prolonged or excessive stimulation.

When receptors are continuously exposed to high levels of an agonist, cells often compensate by reducing the number of receptors on the cell surface (downregulation) or making existing receptors less responsive (desensitization). This is why research studies often use pulsatile or cyclical administration rather than continuous exposure. For example, GHRH receptors downregulate with continuous GHRH stimulation — this is why pulse administration is studied more than continuous infusion for GH secretagogues.

Rapid, short-term reduction in response to a compound following initial administration.

Tachyphylaxis is an acute form of tolerance — a diminishing response that occurs within a short time window (minutes to hours) of repeated dosing. Different from chronic tolerance which develops over days-weeks. Mechanistically, it can result from receptor desensitization, receptor internalization, or depletion of neurotransmitter stores. In peptide research, tachyphylaxis has been studied for GHRP compounds where rapid sequential dosing produces diminishing GH pulses.

Largest receptor superfamily in the human genome. Most peptide hormones act through GPCRs.

GPCRs are transmembrane receptors that couple to intracellular G proteins upon ligand binding. The G protein then activates secondary messengers (cAMP, IP3, DAG) to produce cellular responses. The GLP-1 receptor, ghrelin receptor (GHSR), melanocortin receptors (MC1R-MC5R), GnRH receptor, and KISS1R are all GPCRs. Over 30% of approved drugs target GPCRs, highlighting their pharmaceutical importance. GPCR activation and desensitization mechanisms are critical for understanding peptide pharmacology.

Central kinase that integrates nutrient, energy, and growth factor signals to regulate cell growth and metabolism.

mTOR exists in two complexes (mTORC1 and mTORC2) with distinct functions. mTORC1 promotes protein synthesis, cell growth, and inhibits autophagy in response to nutrients and growth factors (including IGF-1). mTORC2 regulates cell survival and metabolism. In longevity research, mTOR inhibition (by rapamycin or caloric restriction) is associated with lifespan extension in model organisms. mTOR activation is anabolic; inhibition promotes autophagy and cellular recycling.

Cellular energy sensor that activates catabolic pathways and inhibits anabolic pathways when energy is low.

AMPK is activated when the AMP:ATP ratio increases (low energy state). It promotes fatty acid oxidation, glucose uptake, mitochondrial biogenesis, and autophagy — essentially a "fuel-efficiency" program. MOTS-c, exercise, and caloric restriction all activate AMPK. AMPK opposes mTOR, creating a see-saw relationship between growth (mTOR) and maintenance/recycling (AMPK). Many longevity interventions are thought to work partly through AMPK activation.

Cellular self-cleaning process that degrades and recycles damaged proteins and organelles.

Autophagy (Greek: "self-eating") is a lysosomal degradation pathway that removes cellular debris: damaged proteins, dysfunctional mitochondria (mitophagy), and excess organelles. Activated by nutrient deprivation, exercise, and mTOR inhibition. Reduced autophagy with aging is associated with accumulation of cellular damage. Research into peptides that modulate autophagy is active in longevity science. Rapamycin's lifespan-extending effects in mice appear partly mediated through autophagy enhancement.

A state of permanent cell cycle arrest that cells enter in response to stress or damage.

Senescent cells stop dividing but remain metabolically active, secreting a complex mixture of inflammatory cytokines, chemokines, and proteases called the SASI (Senescence-Associated Secretory Phenotype). Over time, senescent cell accumulation is believed to drive tissue dysfunction and inflammaging. Senolytics (compounds that selectively eliminate senescent cells) are an active research area in longevity science. GHK-Cu and epithalon have been studied in the context of senescence modulation.

Chronic, low-grade systemic inflammation that increases with aging and drives many age-related diseases.

Inflammaging (portmanteau of inflammation + aging) describes the chronic, sterile, low-grade inflammatory state that characterizes aging. Driven by senescent cells (SASP), mitochondrial dysfunction, gut dysbiosis, and accumulated cellular damage. Associated with increased IL-6, TNF-α, CRP, and other inflammatory markers. Most age-related diseases (cardiovascular, metabolic, neurological, cancer) share inflammaging as a common driver. Anti-inflammatory peptides studied for longevity include KPV, ARA-290, and thymosin alpha-1.

Coenzyme found in all living cells, critical for energy metabolism, DNA repair, and cellular signaling.

NAD+ declines significantly with aging (up to 50% reduction by middle age). Functions as an electron carrier in cellular respiration (converting to NADH), a substrate for sirtuin deacetylases (SIRT1-7), and a substrate for PARP enzymes involved in DNA repair. NAD+ supplementation research focuses on precursors (NMN, NR) and direct IV/IM administration. Research shows NAD+ precursor supplementation increases tissue NAD+ levels in humans, though functional outcomes vary by study.

Laboratory document verifying the composition, purity, and potency of a research compound.

A COA is an analytical document from a qualified laboratory that confirms a compound's identity, purity (typically by HPLC), potency, and absence of contaminants. For research peptides, key COA parameters include: peptide content (%), HPLC purity (%), residual solvents, heavy metals, and endotoxin levels. Legitimate research supply companies provide COAs from independent third-party laboratories, not just manufacturer self-testing. When evaluating research compound sourcing, COA transparency is the primary quality indicator.

Analytical technique used to separate, identify, and quantify compounds in a mixture.

HPLC separates mixture components based on their differential affinity for a stationary phase vs. a mobile phase. For peptide purity analysis, reverse-phase HPLC (RP-HPLC) is standard. Results show a chromatogram with peaks representing different compounds — the target peptide peak area is compared to total peak area to express purity as a percentage. Pharmaceutical-grade peptides typically require >98% HPLC purity. Research-grade compounds often fall in the 95-99%+ range. HPLC data should be on any legitimate COA.

Testing for bacterial endotoxins (LPS) that cause fever and inflammatory responses even without live bacteria.

Endotoxins are lipopolysaccharides (LPS) from gram-negative bacterial cell walls. They remain potent even after bacteria are killed. When injected, endotoxins can cause fever, inflammation, septic shock, and death at high levels. Research-grade injectables require endotoxin testing (typically LAL or recombinant factor C test). Acceptable limits for injectable compounds are typically <0.1-1 EU/mL depending on intended use. Endotoxin presence is a key quality control concern for research peptide supply.

Protective caps on chromosome ends that shorten with each cell division — a biological clock of cellular aging.

Telomeres are repetitive DNA sequences (TTAGGG) that protect chromosome ends from degradation. Each cell division shortens telomeres slightly. When telomeres become critically short, cells enter senescence or apoptosis. Telomere length is associated with biological aging — shorter telomeres correlate with age-related disease risk in epidemiological studies. Epithalon and other peptides are studied for potential telomerase-activating properties that might theoretically slow telomere shortening.

The process by which cells increase their number of mitochondria in response to energy demands.

Mitochondrial biogenesis is controlled primarily by PGC-1α, a transcriptional coactivator activated by exercise, cold exposure, caloric restriction, and AMPK activation. More mitochondria means greater cellular energy production capacity. Aging is associated with mitochondrial dysfunction and reduced biogenesis. Research peptides studied in the context of mitochondrial biogenesis include MOTS-c (AMPK activator), SS-31 (inner membrane stabilizer), and NAD+ precursors (sirtuin activators including SIRT1, which activates PGC-1α).

A standardized unit of biological activity used for hormones, vitamins, and biologics where mass alone doesn't reflect potency.

IUs are defined by international standards based on biological activity rather than weight. Different compounds have different IU:mass relationships. For HCG, 1 IU ≠ 1mcg — the IU reflects LH-equivalent biological activity. For HGH, 1mg is approximately 3 IU (approximate, varies by preparation). For vitamin D, 1 IU = 0.025mcg. This is why understanding which unit system a study uses is critical for interpreting research — a "dose" in IUs cannot be compared to a "dose" in mg without knowing the specific conversion for that compound.

A compound that binds to a receptor and activates it, producing a biological response.

An agonist mimics or amplifies the effect of the body's natural signaling molecules. Full agonists produce the maximum possible receptor activation. Partial agonists activate the receptor but produce a submaximal response even at saturation. The distinction matters in research because partial agonists can act as functional antagonists by occupying receptors without fully activating them. GLP-1 receptor agonists like semaglutide are full agonists at the GLP-1 receptor.

The formation of new blood vessels from pre-existing vasculature — essential for wound healing and tissue repair.

Angiogenesis is triggered by signals including VEGF (Vascular Endothelial Growth Factor), FGF, and PDGF. New blood vessels supply nutrients and oxygen to healing tissue. BPC-157 is one of the most studied research peptides for its proposed pro-angiogenic effects, particularly via VEGF upregulation. Pathological angiogenesis occurs in cancer and diabetic retinopathy, making angiogenesis a complex two-sided research area.

A compound that blocks a receptor without activating it, preventing endogenous or exogenous agonists from binding.

Antagonists occupy receptor binding sites competitively (reversible) or non-competitively (irreversible), blocking the receptor's activation. Unlike agonists, they do not trigger a response — they prevent one. Competitive antagonists can be overcome by increasing agonist concentration; non-competitive antagonists cannot. In peptide research, understanding the antagonist/agonist distinction is critical for interpreting mechanism studies that use receptor blockers to confirm which pathway a peptide acts through.

The fundamental building blocks of peptides and proteins. Twenty standard amino acids combine in different sequences to create all biological peptides.

Amino acids share a common structure: a central carbon (alpha-carbon) bonded to an amino group (-NH2), a carboxyl group (-COOH), a hydrogen, and a variable side chain (R group). The R group determines each amino acid's properties — charged, polar, nonpolar, aromatic. Peptide bonds form between the carboxyl of one amino acid and the amino group of the next, with water released. The sequence and composition of amino acids determines a peptide's three-dimensional shape, receptor affinity, and function.

Sterile water containing 0.9% benzyl alcohol, used to reconstitute lyophilized peptides for research purposes.

Bacteriostatic water differs from sterile water in that benzyl alcohol (0.9%) acts as a preservative, inhibiting bacterial growth. This allows a single vial to be used multiple times over several weeks once opened (typically up to 28 days when refrigerated), unlike regular sterile water which should be used immediately after opening. The benzyl alcohol also has mild local anesthetic properties. Critical consideration: benzyl alcohol may degrade certain sensitive peptides — some researchers prefer sterile water or sodium chloride for specific compounds.

A selective semipermeable border that separates circulating blood from brain tissue, protecting the CNS from many compounds.

The BBB is formed by specialized endothelial cells with tight junctions that restrict passive diffusion. Small, lipophilic, uncharged molecules cross most readily. Most peptides (large, hydrophilic) have poor BBB penetration unless specifically designed for CNS delivery. Semax and Selank achieve meaningful CNS effects when administered intranasally partly due to direct olfactory nerve transport bypassing the BBB. PT-141's central melanocortin activity suggests some CNS penetration via intranasal route.

Second messenger molecule that relays signals from GPCRs to intracellular targets, regulating a wide array of cellular processes.

cAMP is produced when Gs-coupled GPCRs activate adenylyl cyclase, converting ATP to cAMP. It then activates protein kinase A (PKA), which phosphorylates numerous target proteins. cAMP signaling mediates effects of glucagon, TSH, FSH, LH, CRH, and many other hormones. GLP-1 receptor activation produces cAMP as its primary second messenger, which drives glucose-dependent insulin secretion. cAMP-PDE inhibitors (like theophylline) amplify cAMP signals by preventing its degradation.

Most abundant protein in the body. Forms the structural scaffolding of connective tissue, skin, bone, tendons, and cartilage.

Collagen is a triple-helix protein made from collagen alpha chains rich in glycine-proline-hydroxyproline repeats. Over 28 types exist (Type I dominant in skin/bone, Type II in cartilage, Type III in blood vessels). GHK-Cu (copper peptide) is among the most studied research compounds for its ability to upregulate collagen and elastin gene expression. Vitamin C is essential for collagen hydroxylation — deficiency causes scurvy. Research into peptides for collagen synthesis is active in wound care, dermatology, and musculoskeletal medicine.

The brain and spinal cord — the primary information-processing and regulatory center of the human body.

The CNS integrates information from the peripheral nervous system, endocrine system, and immune system. Many research peptides studied for cognitive, mood, and neuroprotective effects target CNS receptors. PT-141 acts on melanocortin receptors in the CNS to produce sexual arousal responses. Semax and Selank modulate BDNF and GABAergic pathways centrally. Achieving CNS drug concentrations is challenging due to BBB restrictions — intranasal administration is studied as a CNS delivery route for several peptides.

A research administration pattern that alternates between active and washout periods to preserve receptor sensitivity and avoid tachyphylaxis.

Cyclical protocols are common in peptide research design. Examples: Epithalon studied in 10-day cycles with 1-4 month gaps; GHRPs studied with on/off patterns to avoid GH receptor desensitization. The scientific rationale involves receptor recycling, restored sensitivity, and avoiding chronic suppression of endogenous production. Research cycle lengths vary widely — some literature uses 4-weeks-on/4-weeks-off, others use 3 months on with 1 month off. Protocol design should reference specific published study parameters for each compound.

Peptides composed of exactly two or three amino acids, respectively. Among the simplest functional peptide structures.

Dipeptides (2 AA) and tripeptides (3 AA) are the smallest functional peptide units. Despite their small size, they can exert potent biological effects. KPV (Lys-Pro-Val) is a tripeptide with studied anti-inflammatory properties. GHK (Gly-His-Lys) is a tripeptide with broad tissue-remodeling research. Pinealon (Glu-Asp-Arg) and Vilon (Lys-Glu) are dipeptide/tripeptide combinations from Russian longevity research. Small size generally improves oral bioavailability compared to larger peptides.

Reduced response to a compound following repeated or prolonged exposure, due to receptor-level changes rather than reduced compound concentration.

Receptor desensitization involves several mechanisms: phosphorylation of the receptor by GRKs (GPCR kinases), recruitment of beta-arrestins which sterically block G protein coupling, and receptor internalization (endocytosis). Different from pharmacokinetic tolerance (metabolism increases). Desensitization is time-dependent — short intervals between doses more likely to produce it. Understanding desensitization kinetics is critical for research protocol design, particularly for compounds targeting GPCRs like GLP-1R, ghrelin receptor, and melanocortin receptors.

The non-cellular structural scaffolding that surrounds and supports cells in tissues — composed of collagens, proteoglycans, and glycoproteins.

The ECM provides structural support, mediates cell signaling, and controls cell behavior. Key components: fibrous proteins (collagen, elastin), adhesive glycoproteins (fibronectin, laminin), and proteoglycans (hyaluronic acid, aggrecan). Matrix metalloproteinases (MMPs) remodel the ECM during wound healing — BPC-157 and TB-500 both modulate MMP activity. ECM disruption underlies fibrosis, aging-related tissue stiffness, and impaired wound healing. Research peptides for ECM modulation are studied across dermatology, orthopedics, and cardiology.

The ranked classification of scientific evidence quality, from anecdote to systematic meta-analysis.

From weakest to strongest: Anecdote/case report → Case series → Cross-sectional study → Case-control study → Cohort study → Randomized Controlled Trial (RCT) → Systematic Review → Meta-analysis. Most research peptides have evidence concentrated in preclinical (animal) studies and case reports, with limited RCT data. GLP-1 agonists (semaglutide, tirzepatide) are exceptional — they have large, multi-phase RCTs placing them at the top of the evidence hierarchy for their specific applications.

Focal Adhesion Kinase signaling pathway that regulates cell migration, adhesion, and survival — key mechanism for BPC-157's tissue repair effects.

FAK (Focal Adhesion Kinase) is activated by integrin receptor engagement when cells contact the ECM. FAK phosphorylates paxillin and other scaffold proteins, initiating signaling cascades that promote cell spreading and migration. BPC-157 research shows it activates the FAK-paxillin pathway specifically in tendon fibroblasts, facilitating their migration to injury sites. This may explain the accelerated tendon healing observed in animal studies. FAK signaling also promotes cell survival (anti-apoptotic) and is involved in angiogenesis.

Primary connective tissue cell responsible for producing collagen, elastin, and other ECM components essential for wound healing.

Fibroblasts are the workhorses of tissue repair. When injury occurs, resident fibroblasts activate and proliferate, producing collagen and other matrix proteins to fill the wound. Myofibroblasts (activated fibroblasts) also contract wounds. GHK-Cu, BPC-157, and TB-500 all show evidence of modulating fibroblast activity in research. Excessive fibroblast activation leads to fibrosis (scar tissue). Balanced fibroblast regulation is the goal of tissue repair research — healing without excessive scarring.

Reduction in stomach acid production — relevant to research on gut-protective peptides and GI health.

The stomach produces hydrochloric acid (HCl) via parietal cells, creating a pH of 1.5-3.5. This is essential for protein digestion and pathogen killing but can damage the gastric mucosa if the protective mucus barrier is compromised. BPC-157 was originally discovered in research on gastric juice protective proteins — its gastroprotective properties are among its most studied attributes, with animal studies showing protection against NSAID-induced ulceration, alcohol damage, and stress ulcers.

The process by which information encoded in DNA is used to synthesize functional proteins or RNA molecules.

Gene expression involves two steps: transcription (DNA → mRNA) and translation (mRNA → protein). Regulatory factors (transcription factors, epigenetic marks, non-coding RNAs) control which genes are expressed, when, and at what level. Research peptides often work by modulating gene expression programs. GHK-Cu is notable for being studied across 4,000+ gene activation/suppression effects. Epithalon is proposed to work through epigenetic gene regulation pathways. Understanding gene expression changes is now routinely studied via RNA sequencing in peptide research.

Hypothalamic peptide that controls reproductive hormone cascades by stimulating pituitary LH and FSH release.

GnRH is released in pulses from the hypothalamus, stimulating pituitary gonadotroph cells to release LH and FSH. LH triggers testosterone production (in males: Leydig cells; in females: corpus luteum) and FSH drives sperm and follicle development. Critically, continuous (non-pulsatile) GnRH receptor stimulation causes receptor downregulation and hormone suppression — this is exploited therapeutically with GnRH agonists for prostate cancer. PT-141 (bremelanotide) acts upstream via melanocortin receptors to influence sexual arousal pathways.

A blood marker reflecting average blood glucose levels over the preceding 2-3 months. Primary outcome measure in diabetes research.

HbA1c forms when glucose non-enzymatically attaches to hemoglobin. Since red blood cells live ~120 days, HbA1c reflects integrated blood glucose control over that period. Normal: <5.7%; Pre-diabetes: 5.7-6.4%; Diabetes: ≥6.5%. GLP-1 receptor agonist trials consistently use HbA1c reduction as a primary endpoint. SURPASS-1 trial: tirzepatide reduced HbA1c by up to 2.6% from baseline at 40 weeks. HbA1c is preferred over single glucose readings as it cannot be manipulated by short-term dietary changes.

A dose-response phenomenon where low doses of a stressor produce beneficial adaptive responses, while high doses are harmful.

Hormesis ("that which excites") describes a biphasic dose-response curve: low stimulation is beneficial, high stimulation is harmful. Examples: low-dose radiation increases stress resistance; exercise (a metabolic stressor) improves fitness; intermittent fasting improves metabolic health. Many peptide research frameworks are based on hormetic principles — pulsatile GH secretagogue administration is studied to produce beneficial GH pulses rather than sustained supraphysiological levels. Senolytic research also applies hormetic thinking to cellular stress responses.

Gut hormones released in response to food intake that amplify insulin secretion in a glucose-dependent manner.

The two main incretins are GLP-1 (from L-cells) and GIP (from K-cells). The incretin effect accounts for 50-70% of postprandial insulin secretion in healthy individuals — explaining why oral glucose produces more insulin than IV glucose (the "incretin effect"). This glucose-dependence is therapeutically important: incretins only stimulate insulin when blood glucose is elevated, dramatically reducing hypoglycemia risk vs. sulfonylureas. Incretin-based therapies (GLP-1RAs, DPP-4 inhibitors, dual/triple agonists) are now foundational to metabolic disease research.

The immune system's first-line protective response to injury or infection — essential for healing but damaging when chronic.

Acute inflammation (redness, heat, swelling, pain) is a protective cascade involving vasodilation, immune cell recruitment, and cytokine release. It clears pathogens and damaged tissue, enabling repair. Chronic inflammation is pathological — sustained cytokine production damages healthy tissue and drives metabolic disease, cardiovascular disease, neurodegeneration, and cancer. Many research peptides are studied for anti-inflammatory properties: KPV (IL-1beta antagonism), BPC-157 (NF-κB modulation), ARA-290 (innate repair receptor), thymalin, and TB-500.

Drug delivery via the nasal mucosa — studied for peptides requiring CNS access or rapid absorption without injection.

Intranasal delivery offers several advantages: avoids first-pass hepatic metabolism, bypasses BBB via olfactory and trigeminal nerve pathways, enables rapid absorption through highly vascularized nasal mucosa. Particularly relevant for CNS-targeted peptides: Semax and Selank (Russian nootropic peptides) are formulated as nasal drops specifically because they achieve meaningful CNS concentrations via this route. PT-141 (bremelanotide) received FDA approval as an intranasal formulation before transitioning to subcutaneous. Nasal bioavailability varies widely (5-80%) depending on molecular properties.

Neuropeptide encoded by the KISS1 gene that acts as a master regulator of reproductive hormone release via GnRH neurons.

Kisspeptin neurons in the hypothalamus (arcuate nucleus and AVPV) integrate metabolic and hormonal signals to regulate GnRH pulse frequency and amplitude. Kisspeptin-10 and Kisspeptin-54 are research variants studied for their role in reproductive endocrinology, sexual behavior, and HPA axis regulation. Kisspeptin administration in human studies robustly stimulates LH release. Research interest in kisspeptin spans reproductive disorders, psychosexual function, and understanding metabolic-reproductive axis interactions.

A dehydration preservation process that removes water from a compound under vacuum, leaving a stable dry powder.

Lyophilization sublimes water directly from ice to vapor under low pressure and temperature. The result is a porous, dry "cake" or powder that retains the compound's structure and bioactivity. Most research peptides are lyophilized for stability — they can be stored as powder at refrigerator or freezer temperatures for extended periods (months to years). Reconstitution is required before use by adding an appropriate aqueous vehicle (bacteriostatic water, sterile water). Lyophilized peptides are sensitive to moisture, heat, and UV light.

An initial higher dose given to rapidly reach therapeutic concentrations, followed by maintenance doses to sustain those levels.

For compounds with long half-lives, reaching steady state through regular maintenance dosing takes 4-5 half-lives — potentially weeks. A loading dose front-loads the compound to quickly achieve target concentrations. For semaglutide (7-day t½), steady state without loading would take ~5-6 weeks. Clinical protocols often use gradual titration instead of true loading doses for GLP-1 agonists to minimize GI side effects. Loading strategies are also used in some peptide research cycles for compounds with very short half-lives where rapid saturation of target systems is studied.

Analytical technique that identifies compounds by measuring the mass-to-charge ratio of ionized molecules with extreme precision.

Mass spectrometry separates ions based on their mass-to-charge ratio (m/z), producing a characteristic "fingerprint" spectrum for each compound. For peptides, LC-MS/MS (liquid chromatography coupled with tandem MS) can confirm exact molecular weight, amino acid sequence, and detect impurities or modifications. A COA with MS data alongside HPLC provides the highest confidence in compound identity. MS can detect substitutions or truncations that HPLC alone might miss — critical for research compound authentication.

A family of receptors (MC1R-MC5R) and their endogenous ligands (α-MSH, β-MSH, γ-MSH, ACTH) regulating pigmentation, sexual function, inflammation, and energy balance.

The melanocortin system involves 5 receptor subtypes with distinct tissue distributions: MC1R (pigmentation in melanocytes), MC2R (ACTH receptor in adrenal glands), MC3R (energy balance in hypothalamus), MC4R (food intake, sexual function, energy), MC5R (exocrine glands). PT-141 (bremelanotide) acts on MC3R and MC4R to produce sexual arousal responses — the first CNS-targeted sexual dysfunction peptide. Melanotan II also targets this system with broader receptor engagement. MC4R agonism is intensely studied for obesity treatment.

The protective lining of hollow organs (gut, respiratory tract, urogenital tract) that prevents pathogen invasion and regulates absorption.

The mucosal barrier consists of multiple layers: an outer mucus gel layer (from goblet cells), a single layer of epithelial cells connected by tight junctions, and an underlying immune cell-rich lamina propria. The gut mucosal barrier is particularly critical — a 1-cell-thick layer separating gut contents from systemic circulation. Disruption ("leaky gut" / increased intestinal permeability) allows bacterial products (LPS) to enter circulation, triggering inflammation. BPC-157 is extensively studied for mucosal barrier restoration in animal models of colitis, NSAID damage, and alcohol injury.

Mechanisms and interventions that preserve neuronal function and prevent neuron death from injury, disease, or aging.

Neuroprotective strategies include antioxidant defense, anti-inflammatory actions, neurotrophic factor support (BDNF, NGF), mitochondrial protection, and excitotoxicity prevention. Research peptides studied for neuroprotective properties include: Semax (increases BDNF, studied in stroke recovery), Selank (anxiolytic, studied in PTSD models), Pinealon (from Russian neuroprotection research), Dihexa (NGF-potentiating hexapeptide), and MOTS-c (mitochondrial protection in neuronal models). The blood-brain barrier presents the primary challenge for CNS-targeted peptide delivery.

A gaseous signaling molecule produced by nitric oxide synthase enzymes, with roles in vasodilation, immune function, and neurotransmission.

NO is synthesized from arginine by three NOS isoforms: eNOS (endothelial — vasodilation), nNOS (neuronal — neurotransmission), iNOS (inducible — immune response). eNOS-derived NO relaxes vascular smooth muscle, reducing blood pressure and increasing blood flow. BPC-157 modulates NO synthesis — research shows it can both stimulate and normalize NO production depending on the research model context. This NO modulation may explain its observed effects on blood pressure and tissue perfusion in animal studies.

Direct NAD+ precursor that efficiently raises intracellular NAD+ levels. Extensively studied for anti-aging, metabolic, and cognitive health research.

NMN is phosphorylated to NMN-dinucleotide (NMND) and then to NAD+ inside cells. As a direct precursor, NMN can raise NAD+ faster than more distal precursors like tryptophan. Human trials have demonstrated that oral NMN supplementation significantly elevates NAD+ metabolites in blood and muscle tissue. Japanese RCT (Igarashi 2022): 250mg/day NMN improved muscle insulin sensitivity and physical performance metrics in older adults. Note: NMN vs. NR (nicotinamide riboside) comparative research is ongoing.

Unintended biological effects of a compound acting at receptors or pathways other than its primary target.

No compound is perfectly specific. Off-target effects can be beneficial (an anti-diabetes drug that also protects the heart, as seen with GLP-1 agonists) or adverse. Understanding off-target profiles requires systematic receptor binding studies and broad safety pharmacology. For research peptides, off-target effects are often unknown or understudied because comprehensive receptor panels aren't typically part of early preclinical work. This is a key limitation cited when discussing research peptides' overall safety and effect profiles.

The covalent bond formed between the carboxyl group of one amino acid and the amino group of another, with loss of a water molecule.

Peptide bonds are amide bonds (-CO-NH-) that link amino acids into chains. The bond has partial double-bond character due to electron delocalization, making it planar and relatively rigid. This rigidity constrains peptide backbone conformation. Peptide bonds are cleaved by proteases (hydrolysis), which is why orally administered peptides are typically degraded in the gut. Chemical modifications that protect peptide bonds (N-methylation, D-amino acid substitution, cyclization) are research strategies to improve oral or metabolic stability.

The study of what a compound does to the body — its mechanisms of action, receptor binding, and biological effects.

Pharmacodynamics is the companion to pharmacokinetics. While PK asks "what does the body do to the drug?", PD asks "what does the drug do to the body?" Key PD parameters: Emax (maximum effect), EC50 (concentration producing 50% maximum effect), receptor binding affinity (Kd, Ki), and the dose-response relationship. Understanding PD requires knowing which receptors a compound engages, with what affinity, and what the downstream signaling consequences are. PK/PD modeling combines both to predict effects over time.

The sequential stages of human clinical testing required before regulatory approval, each with distinct objectives and scale.

Phase 1: First-in-human safety and PK studies in small groups (20-80 subjects). Phase 2: Efficacy signal and dose-finding in hundreds of patients. Phase 3: Large-scale (hundreds to thousands) randomized controlled trials vs. placebo or active comparator — the basis for regulatory approval. Phase 4: Post-marketing surveillance after approval to identify rare adverse events in real-world populations. Most research peptides discussed on this platform are in preclinical, Phase 1, or Phase 2 stages. GLP-1 agonists have extensive Phase 3 and 4 data.

Laboratory and animal studies conducted before human trials to establish safety, efficacy signals, and mechanistic understanding.

Preclinical research is divided into in vitro (cell culture) and in vivo (animal model) studies. In vitro is fastest and cheapest but least representative of human physiology. Rodent models (mice, rats) are most common, with larger animal models (dogs, pigs, primates) for later-stage work. Critically, many preclinical findings do not translate to humans — an estimated 95% of cancer drugs that pass preclinical testing fail in human trials. Most research peptides outside the GLP-1 class are primarily at the preclinical stage. This is why evidence hierarchy assessment matters.

The enzymatic breakdown of peptides and proteins by proteases — the primary reason most peptides cannot be taken orally.

Proteases are ubiquitous: in digestive secretions (pepsin, trypsin, chymotrypsin), in blood (DPP-4, NEP, ACE), and intracellularly. Most therapeutic peptides are rapidly cleaved by proteases, limiting their half-life and restricting delivery to injectable routes. Semaglutide overcomes this through C-18 fatty acid conjugation (albumin binding) and selective amino acid modifications. Research strategies to resist proteolysis include: D-amino acid substitution, PEGylation, cyclization, and N-terminal acetylation. Understanding proteolytic stability is essential for interpreting peptide pharmacokinetic data.

Hormonal release in discrete bursts rather than continuously — the natural pattern for many hormones including GH, GnRH, LH, and insulin.

Pulsatile secretion is physiologically important because continuous receptor stimulation leads to desensitization. The pituitary gland releases GH in 6-12 pulses per day (largest pulse shortly after sleep onset). GnRH must be pulsatile to maintain gonadotropin secretion — continuous GnRH agonist exposure paradoxically suppresses LH/FSH. Research into GHRH and GHRP combinations aims to amplify these natural GH pulses rather than create continuous supraphysiological exposure. Mimicking natural pulsatile patterns is a key design principle in hormone research.

The gold standard of clinical evidence — participants are randomly assigned to treatment or control groups to minimize bias.

RCT design features that reduce bias: randomization (eliminates selection bias), blinding (reduces performance and detection bias), placebo/active control comparison (establishes true treatment effect), pre-specified endpoints (prevents cherry-picking outcomes). Double-blind RCTs (neither participants nor researchers know allocation) are the strongest single-study design. The GLP-1 agonist trial programs (STEP, SUSTAIN, SURMOUNT, SELECT) are landmark RCTs with tens of thousands of participants and years of follow-up. Most research peptides lack this level of evidence.

The process of dissolving a lyophilized (freeze-dried) peptide powder in an aqueous solution for research administration.

Standard reconstitution process: allow refrigerated vial to reach room temperature; draw appropriate volume of bacteriostatic water into syringe; inject slowly down the vial wall (not directly onto the powder); gently swirl (never shake — shaking damages peptide structure through mechanical stress); allow to fully dissolve; store refrigerated. Concentration is calculated as: mg of peptide ÷ mL of added water = mg/mL. For example: 5mg peptide + 2mL BAC water = 2.5mg/mL = 2,500mcg/mL. Critical: use sterile technique throughout.

The degree to which a compound preferentially acts on one receptor subtype over others in the same family.

Receptor selectivity is critical for predicting a compound's effect profile. Ipamorelin is considered "selective" among GHRPs because it stimulates GH release with minimal cortisol or prolactin elevation — unlike GHRP-6 or hexarelin. Semaglutide is highly selective for GLP-1R over GLP-2R, GIP-R, and glucagon receptor. Tirzepatide intentionally lacks selectivity between GIP-R and GLP-1R. Selectivity is quantified by affinity ratios (Ki for target receptor vs. Ki for off-target receptors). Higher selectivity generally correlates with more predictable effect profiles.

A family of NAD+-dependent deacetylase enzymes (SIRT1-7) central to aging, metabolism, DNA repair, and stress resistance.

Sirtuins require NAD+ as a cosubstrate to function, linking cellular energy status to epigenetic regulation. SIRT1 activates PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), and p53 (DNA repair). SIRT3 maintains mitochondrial function. SIRT6 is essential for DNA double-strand break repair and telomere maintenance. Declining NAD+ with age reduces sirtuin activity, contributing to the aging phenotype. NAD+ precursor supplementation research aims to restore sirtuin activity as a longevity intervention.

Inhibitory peptide produced in the hypothalamus, pancreas, and gut that suppresses GH, insulin, and glucagon release.

Somatostatin (also called growth hormone-inhibiting hormone, GHIH) provides the off-signal in GH regulation, balancing GHRH's stimulatory effects. Endogenous somatostatin release is triggered by high GH levels (negative feedback), hyperglycemia, and high fat/protein intake. Pharmaceutical somatostatin analogues (octreotide, lanreotide) suppress GH in acromegaly treatment. Understanding somatostatin helps explain why timing of research protocols matters — factors that elevate somatostatin (glucose, fatty acids) theoretically blunt GH responses to secretagogues.

A set of practices used to prevent microbial contamination during compound preparation and administration.

Key sterile technique principles: work in a clean, draft-free area; wash hands thoroughly; use alcohol wipes on all vial tops and injection sites; use sterile, single-use needles and syringes; never touch needle tips or allow them to contact non-sterile surfaces; use a 0.22-micron filter syringe (Whatman-style) to additionally filter reconstituted compounds before use; discard opened sterile water vials promptly; refrigerate reconstituted peptides. Sterility failures in research settings can introduce bacteria and endotoxins — the primary preventable source of injection-site infections and systemic reactions.

Gradual increase of a compound's quantity over time to minimize adverse effects while reaching target levels.

Titration protocols start below the target study quantity and increase incrementally over weeks. GLP-1 agonist trials use structured titration (e.g., semaglutide: 0.25mg/week x4 → 0.5mg/week x4 → 1mg/week x4 → 2.4mg final maintenance). This approach reduces the incidence of GI side effects by allowing adaptation. The trade-off is delayed onset of full effect. Titration schedules in research literature vary by compound — BPC-157 and TB-500 protocols typically don't require titration given their short half-lives and absence of receptor desensitization concerns.

Pro-inflammatory cytokine produced primarily by macrophages. A central mediator of acute and chronic inflammation.

TNF-α drives fever, systemic inflammation, and is a master regulator of other pro-inflammatory cytokines. Chronically elevated TNF-α (as in obesity, metabolic syndrome, arthritis) drives insulin resistance, muscle wasting, and tissue damage. TNF-α inhibitors (biologics like etanercept, adalimumab) are among the most commercially successful drugs. In peptide research, several compounds including KPV, ARA-290, and BPC-157 show evidence of modulating TNF-α production or signaling in preclinical models.

Primary signaling protein driving angiogenesis — the formation of new blood vessels.

VEGF (primarily VEGF-A) binds VEGFR-2 on endothelial cells, triggering proliferation, migration, and tube formation. Critical for wound healing (supplying new blood vessels to healing tissue), normal development, and physiological adaptation to exercise. BPC-157 research consistently shows VEGF upregulation as a proposed mechanism for its tissue repair effects. Pathological VEGF overexpression drives tumor angiogenesis (cancer blood supply) and diabetic retinopathy. Anti-VEGF therapies are standard-of-care for these conditions.

A period without compound administration to allow clearance and restore receptor sensitivity before a new study phase.

Washout periods eliminate carryover effects between study periods. Duration should be at least 5 half-lives of the compound to ensure >97% clearance. For semaglutide (7-day t½), a full washout requires ~5 weeks. For short half-life peptides (BPC-157, ipamorelin), washout is rapid. Crossover trial designs require carefully calculated washout periods between each treatment phase. In research cycles, washout periods also serve the biological function of restoring receptor sensitivity and endogenous production.